Jane Wolstenholme

Sep 30, 2024 | nature.com | Richard McManus |Clare Taylor |Nicholas Jones |Jane Wolstenholme |Sungwook Kim |Joseph Sang-II Kwon | +2 more

AbstractChronic kidney disease (CKD) is associated with a substantial risk of progression to end-stage renal disease and vascular events. The nonsteroidal mineralocorticoid receptor antagonist (MRA), finerenone, offers cardiorenal protection for people with CKD and diabetes, but there is uncertainty if the steroidal MRA, spironolactone, provides the same protection.

Aug 2, 2024 | lexology.com | Jane Wolstenholme

With the new Parliament now in recess until 2 September, MPs are traditionally going back to their constituencies, although we expect the new ministers will also be spending time with their departments identifying what needs to be done to take forward the Labour government’s agenda.